AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33988508 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 23
Study 33988513 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS and HBPM (n=12)
Number of subjects: 24
Study 33988513 — intervention group
Group type: COMPARATOR
Intervention: Usual care and HBPM (n=12)
Number of subjects: 24
Study 33988517 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital Cognitive Behavioral Therapy (CBT)
Number of subjects: 350
Study 33988517 — intervention group
Group type: COMPARATOR
Intervention: Education
Number of subjects: 350
Study 33988517 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital CBT
Number of subjects: 350
Study 33988847 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation strategies identified through Innovation Tournament (IT) with agency staff stakeholders.
Number of subjects: 26
Study 33988847 — intervention group
Group type: EXPERIMENTAL
Intervention: Engagement strategies for parents and youth.
Number of subjects: 26
Study 33988881 — intervention group
Group type: EXPERIMENTAL
Intervention: Vismodegib treatment
Number of subjects: 34
Study 33988881 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery post-Vismodegib treatment
Number of subjects: 34
Study 33988944 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized variability- and chronobiology-based therapy for analgesics
Number of subjects: 0
Study 33988944 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronotherapy based on circadian rhythm
Number of subjects: 0
Study 33989296 — intervention group
Group type: COMPARATOR
Intervention: Brushing, dental floss, and tongue scraper
Number of subjects: 88
Study 33989296 — intervention group
Group type: EXPERIMENTAL
Intervention: Brushing, dental floss, and aPDT
Number of subjects: 88
Study 33989296 — intervention group
Group type: EXPERIMENTAL
Intervention: Brushing, dental floss, and probiotics
Number of subjects: 88
Study 33989296 — intervention group
Group type: EXPERIMENTAL
Intervention: Brushing, dental floss, aPDT, and probiotics
Number of subjects: 88
Study 33989558 — intervention group
Group type: EXPERIMENTAL
Intervention: Loncastuximab tesirine (150 μg/kg for two cycles, then 75 μg/kg thereafter, intravenously on day 1 of each 21-day cycle)
Number of subjects: 145
Study 33989558 — intervention group
Group type: EXPERIMENTAL
Intervention: Loncastuximab tesirine
Number of subjects: 145
Study 33989764 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzyl isothiocyanate (BITC)
Number of subjects: 0
Study 33989764 — intervention group
Group type: EXPERIMENTAL
Intervention: BITC in combination with other drugs
Number of subjects: 0
Study 33990027 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased presence of intervillous fibrin
Number of subjects: 0
Study 33990027 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased placental syncytial knotting
Number of subjects: 0
Study 33990027 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized morphological study of post-date placentas
Number of subjects: 0
Study 33990076 — intervention group
Group type: EXPERIMENTAL
Intervention: e-CBT program delivered through the Online Psychotherapy Tool, 12 weekly sessions tailored to MDD.
Number of subjects: 110
Study 33990076 — intervention group
Group type: COMPARATOR
Intervention: In-person CBT, 12 weekly sessions.
Number of subjects: 110
Study 33990084 — intervention group
Group type: EXPERIMENTAL
Intervention: iPlan Flow software for estimating infusate distribution
Number of subjects: 10
Study 33990101 — intervention group
Group type: EXPERIMENTAL
Intervention: Stopping disease-modifying therapies (DMTs)
Number of subjects: 0
Study 33990364 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone
Number of subjects: 1190987
Study 33990364 — intervention group
Group type: COMPARATOR
Intervention: Control (no domperidone)
Number of subjects: 1190987
Study 33990413 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive revascularisation (186 patients, 85.7%)
Number of subjects: 217
Study 33990413 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive management
Number of subjects: 217
Study 33990415 — intervention group
Group type: EXPERIMENTAL
Intervention: 120mg/kg cyclophosphamide and 125mg/m2 fludarabine
Number of subjects: 0
Study 33990415 — intervention group
Group type: EXPERIMENTAL
Intervention: 60mg/kg cyclophosphamide and 125mg/m2 fludarabine
Number of subjects: 0
Study 33990415 — intervention group
Group type: EXPERIMENTAL
Intervention: 30mg/kg cyclophosphamide and 75mg/m2 fludarabine
Number of subjects: 0
Study 33990415 — intervention group
Group type: EXPERIMENTAL
Intervention: Total body irradiation (TBI) and 75mg/m2 fludarabine
Number of subjects: 0
Study 33990496 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-positive participants
Number of subjects: 358
Study 33990496 — intervention group
Group type: COMPARATOR
Intervention: HIV-negative participants
Number of subjects: 358
Study 33990507 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelin receptor antagonists (ERA), specifically atrasentan, in addition to blockade of the renin-angiotensin-aldosterone system
Number of subjects: 0
Study 33990507 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelin receptor antagonists (ERA)
Number of subjects: 0
Study 33990512 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclisiran
Number of subjects: 0
Study 33990512 — intervention group
Group type: COMPARATOR
Intervention: PCSK9-blocking monoclonal antibodies
Number of subjects: 0
Study 33990649 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined model incorporating automated volumes of selected brain regions on MRI and SUVRs of Braak ROIs on [18F] THK-5351 PET
Number of subjects: 113
Study 33990649 — intervention group
Group type: COMPARATOR
Intervention: SUVRs of Braak ROIs on [18F] THK-5351 PET
Number of subjects: 113
Study 33990663 — intervention group
Group type: EXPERIMENTAL
Intervention: 23 mg donepezil sustained release
Number of subjects: 0
Study 33990663 — intervention group
Group type: COMPARATOR
Intervention: 10 mg donepezil immediate release
Number of subjects: 0
Study 33990663 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (SOC) arm
Number of subjects: 0
Study 33991326 — intervention group
Group type: EXPERIMENTAL
Intervention: Apomorphine Sublingual Film (APL) at doses of 15/20/25/30 mg
Number of subjects: 0
Study 33991326 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous Apomorphine (SC-APO) at doses of 2/3/4/5 mg
Number of subjects: 0
Study 33991326 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous Apomorphine-GO (SC-APO-GO) at doses of 2/3/4/5 mg
Number of subjects: 0
Study 33991323 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol/Perindopril single-pill combination (SPC)
Number of subjects: 1892
Study 33991512 — intervention group
Group type: EXPERIMENTAL
Intervention: Enfortumab vedotin (1.25 mg/kg IV on days 1, 8, and 15 of every 28-day cycle)
Number of subjects: 89
Study 33991512 — intervention group
Group type: EXPERIMENTAL
Intervention: Enfortumab vedotin
Number of subjects: 89
Study 33991553 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfusion Index (PI)
Number of subjects: 41
Study 33991553 — intervention group
Group type: COMPARATOR
Intervention: A-line Autoregression Index (AAI)
Number of subjects: 41
Study 33991553 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfusion Index (PI) before intubation
Number of subjects: 41
Study 33991553 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfusion Index (PI) at 10 minutes intraoperatively
Number of subjects: 41
Study 33991553 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfusion Index (PI) during recovery
Number of subjects: 41
Study 33992295 — intervention group
Group type: EXPERIMENTAL
Intervention: Releasing quadratus lumborum muscle
Number of subjects: 30
Study 33992550 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVR with MR regression
Number of subjects: 7303
Study 33992550 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVR with MR persistence
Number of subjects: 7303
Study 33992550 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVR with nonsignificant baseline MR
Number of subjects: 7303
Study 33992550 — intervention group
Group type: EXPERIMENTAL
Intervention: Staged mitral intervention after TAVR
Number of subjects: 7303
Study 33992550 — intervention group
Group type: COMPARATOR
Intervention: No staged mitral intervention after TAVR
Number of subjects: 7303
Study 33992564 — intervention group
Group type: EXPERIMENTAL
Intervention: N-terminal pro-B-type natriuretic peptide-guided titration of guideline-directed medical therapy (GDMT)
Number of subjects: 894
Study 33992564 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 894
Study 33992569 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT)
Number of subjects: 0
Study 33992606 — intervention group
Group type: EXPERIMENTAL
Intervention: Angio-iFR medical software device (Philips, San Diego, US)
Number of subjects: 440
Study 33992635 — intervention group
Group type: EXPERIMENTAL
Intervention: MSICare
Number of subjects: 333
Study 33992635 — intervention group
Group type: COMPARATOR
Intervention: MSISensor
Number of subjects: 333
Study 33993135 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychedelic-assisted therapy
Number of subjects: 0
Study 33993383 — intervention group
Group type: EXPERIMENTAL
Intervention: Alisertib (MLN8237) 100 mg/m² combined with weekly irinotecan (20 mg twice per day on days 1-3 and 8-10)
Number of subjects: 17
Study 33993383 — intervention group
Group type: EXPERIMENTAL
Intervention: Alisertib (MLN8237) combined with weekly irinotecan
Number of subjects: 17
Study 33993651 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver fibrosis assessment
Number of subjects: 0
Study 33993741 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib with trifluridine/tipiracil (TAS-102) combination treatment
Number of subjects: 0
Study 33993741 — intervention group
Group type: EXPERIMENTAL
Intervention: Trifluridine/tipiracil at 25 mg/m2
Number of subjects: 0
Study 33993815 — intervention group
Group type: EXPERIMENTAL
Intervention: Glasdegib (100 mg QD)
Number of subjects: 0
Study 33993815 — intervention group
Group type: EXPERIMENTAL
Intervention: Glasdegib (supratherapeutic concentrations)
Number of subjects: 0
Study 33993815 — intervention group
Group type: EXPERIMENTAL
Intervention: Glasdegib (5-640 mg QD)
Number of subjects: 0
Study 33993815 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 33993853 — intervention group
Group type: EXPERIMENTAL
Intervention: Fucoxanthin, specific dosage and duration not available
Number of subjects: 0
Study 33993853 — intervention group
Group type: COMPARATOR
Intervention: Other carotenoids, specific details not available
Number of subjects: 0
Study 33994087 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33994151 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated Partial Breast Irradiation (APBI) using a single fraction of Multi-Catheter Interstitial High-Dose Rate Brachytherapy (MIB)
Number of subjects: 37
Study 33994208 — intervention group
Group type: EXPERIMENTAL
Intervention: Ministernotomy
Number of subjects: 986
Study 33994208 — intervention group
Group type: COMPARATOR
Intervention: Minithoracotomy
Number of subjects: 986
Study 33994338 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher ideal cardiovascular health (Life's simple 7 score categorized in tertiles: poor, intermediate, ideal)
Number of subjects: 886
Study 33994338 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher ideal cardiovascular health (specifically in men)
Number of subjects: 886
Study 33994338 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher ideal cardiovascular health (not specified for women)
Number of subjects: 886
Study 33995015 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD) up to 800 mg/day for 4 weeks
Number of subjects: 42
Study 33995015 — intervention group
Group type: COMPARATOR
Intervention: Amisulpride (AMI) up to 800 mg/day for 4 weeks
Number of subjects: 42
Study 33995239 — intervention group
Group type: EXPERIMENTAL
Intervention: Epigallocatechin Gallate, dosage and duration not available
Number of subjects: 0
Study 33995239 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 33995257 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33995588 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched targeted therapy based on ctDNA analysis and/or tumor molecular profiling
Number of subjects: 3
Study 33995600 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib 500 mg once daily
Number of subjects: 68
Study 33995597 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 152
Study 33995645 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative assessment of surgical resection margin
Number of subjects: 0
Study 33995645 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 33995988 — intervention group
Group type: EXPERIMENTAL
Intervention: Fostamatinib
Number of subjects: 146
Study 33996511 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided internet-based intervention with CBT and ACT components
Number of subjects: 52
Study 33996511 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 52
Study 33996579 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Oral Feeding (EOF)
Number of subjects: 120
Study 33996579 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Nasojejunal Nutrition (ENN)
Number of subjects: 120
Study 33996579 — intervention group
Group type: COMPARATOR
Intervention: Saline Control
Number of subjects: 120
Study 33996589 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrotinib plus vinorelbine (oral and intravenous)
Number of subjects: 97
Study 33997376 — intervention group
Group type: EXPERIMENTAL
Intervention: 10g FOSS
Number of subjects: 25
Study 33997376 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextrose:FOSS (50:0 or 50:15 or 35:0 or 35:15)
Number of subjects: 25
Study 33997376 — intervention group
Group type: EXPERIMENTAL
Intervention: White-bread:FOSS (50:0 or 50:15 or 35:0 or 35:15)
Number of subjects: 25
Study 33997376 — intervention group
Group type: COMPARATOR
Intervention: Water alone
Number of subjects: 25
Study 33997459 — intervention group
Group type: EXPERIMENTAL
Intervention: Defined menu plans with a cardioprotective diet and additional 3 g of long-chain n-3 PUFA from fish oil
Number of subjects: 60
Study 33997459 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional counseling and incentives
Number of subjects: 60
Study 33997734 — intervention group
Group type: EXPERIMENTAL
Intervention: Dream Warmer (non-electric infant warmer)
Number of subjects: 3179
Study 33997734 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 3179
Study 33997740 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant vismodegib 150 mg administered orally once daily for 4 to 10 months before planned surgery
Number of subjects: 55
Study 33997740 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant vismodegib
Number of subjects: 55
Study 33997741 — intervention group
Group type: EXPERIMENTAL
Intervention: Fevipiprant 150 mg once daily
Number of subjects: 1347
Study 33997741 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1347
Study 33997942 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration of operational strategies with new electronic technologies (e-technologies) in the Beat Acute Myeloid Leukemia Master Trial.
Number of subjects: 0
Study 33997942 — intervention group
Group type: EXPERIMENTAL
Intervention: e-Protocol/e-Source Upload/Electronic Data Capture Platform
Number of subjects: 0
Study 33997942 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Oversight Platform
Number of subjects: 0
Study 33997942 — intervention group
Group type: EXPERIMENTAL
Intervention: Data Review Platform
Number of subjects: 0
Study 33998243 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan (S/V) treatment
Number of subjects: 715
Study 33998257 — intervention group
Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 469
Study 33998257 — intervention group
Group type: EXPERIMENTAL
Intervention: History of migraine
Number of subjects: 469
Study 33998257 — intervention group
Group type: EXPERIMENTAL
Intervention: Age ≥50 years
Number of subjects: 469
Study 33998257 — intervention group
Group type: EXPERIMENTAL
Intervention: History of hypertension
Number of subjects: 469
Study 33998257 — intervention group
Group type: EXPERIMENTAL
Intervention: Involvement of ≥3 vascular beds
Number of subjects: 469
Study 33998257 — intervention group
Group type: EXPERIMENTAL
Intervention: Male sex (pooled analysis)
Number of subjects: 469
Study 33998259 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Mellitus (DM)
Number of subjects: 3688
Study 33998259 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-Diabetes Mellitus (pre-DM)
Number of subjects: 3688
Study 33998259 — intervention group
Group type: EXPERIMENTAL
Intervention: No Diabetes Mellitus (no-DM)
Number of subjects: 3688
Study 33998259 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c levels
Number of subjects: 3688
Study 33998278 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/Valsartan
Number of subjects: 4774
Study 33998278 — intervention group
Group type: COMPARATOR
Intervention: Control (Angiotensin-Receptor Blockers)
Number of subjects: 4774
Study 33998279 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean lumen diameter
Number of subjects: 4668
Study 33998279 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean outer wall diameter
Number of subjects: 4668
Study 33998279 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean wall thickness (MWT)
Number of subjects: 4668
Study 33998279 — intervention group
Group type: EXPERIMENTAL
Intervention: MWT associated with age
Number of subjects: 4668
Study 33998279 — intervention group
Group type: EXPERIMENTAL
Intervention: MWT associated with sex
Number of subjects: 4668
Study 33998279 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumen and outer wall diameters
Number of subjects: 4668
Study 33998279 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumen diameter decrease rate
Number of subjects: 4668
Study 33998340 — intervention group
Group type: EXPERIMENTAL
Intervention: PROMIS® Anxiety Form
Number of subjects: 0
Study 33998340 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized Anxiety Disorder Scale
Number of subjects: 0
Study 33998660 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide (200 mg to 600 mg per day)
Number of subjects: 2199
Study 33998661 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihelminthics (single dose during second trimester)
Number of subjects: 7873
Study 33998661 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihelminthics
Number of subjects: 7873
Study 33998664 — intervention group
Group type: COMPARATOR
Intervention: Combination of daily calf and hamstring stretching for six weeks
Number of subjects: 201
Study 33998664 — intervention group
Group type: COMPARATOR
Intervention: Calf stretching alone for 12 weeks
Number of subjects: 201
Study 33998664 — intervention group
Group type: COMPARATOR
Intervention: Combination of daily calf, quadriceps, and hamstring stretching
Number of subjects: 201
Study 33998674 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin-converting enzyme (ACE) inhibitors (captopril or enalapril)
Number of subjects: 635
Study 33998674 — intervention group
Group type: COMPARATOR
Intervention: Alpha blockers (buflomedil or moxisylyte)
Number of subjects: 635
Study 33998674 — intervention group
Group type: COMPARATOR
Intervention: Prostaglandin/prostacyclin analogues (beraprost)
Number of subjects: 635
Study 33998674 — intervention group
Group type: COMPARATOR
Intervention: Thromboxane synthase inhibitors (dazoxiben)
Number of subjects: 635
Study 33998674 — intervention group
Group type: COMPARATOR
Intervention: Selective serotonin reuptake inhibitors (ketanserin)
Number of subjects: 635
Study 33998674 — intervention group
Group type: COMPARATOR
Intervention: Nitrate/nitrate derivatives (nitroglycerin or glyceryl trinitrate)
Number of subjects: 635
Study 33998674 — intervention group
Group type: COMPARATOR
Intervention: Phosphodiesterase inhibitors (vardenafil, cilostazol or PF-00489791)
Number of subjects: 635
Study 33998859 — intervention group
Group type: EXPERIMENTAL
Intervention: High-potency cannabis
Number of subjects: 0
Study 33998898 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33999158 — intervention group
Group type: EXPERIMENTAL
Intervention: Onasemnogene abeparvovec (therapeutic dose, 1.1×10^14 vg/kg)
Number of subjects: 13
Study 33999158 — intervention group
Group type: EXPERIMENTAL
Intervention: Onasemnogene abeparvovec (low dose, 6.7×10^13 vg/kg)
Number of subjects: 13
Study 33999422 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd) 6.4 mg/kg Q3W
Number of subjects: 337
Study 33999422 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd) 5.4 mg/kg Q3W
Number of subjects: 337
Study 33999422 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd)
Number of subjects: 337
Study 33999564 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative immobilization recommended by 86% (24/28) of surgeons, with 7 different methods identified. 23/24 reported full-time immobilization, most (20/23) for 4 to 6 weeks.
Number of subjects: 28
Study 33999564 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy (PT) for range of motion, strengthening, and return to function recommended by 96% (27/28) of surgeons, starting at a mean of 2.6 weeks postoperatively (range: 0 to 16 weeks).
Number of subjects: 28
Study 33999564 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient rehabilitation available for 75% (21/28) of surgeons, but most (17/21) reported it was accessed by 20% or fewer of their patients.
Number of subjects: 28
Study 33999653 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-based cervicography
Number of subjects: 164
Study 33999698 — intervention group
Group type: EXPERIMENTAL
Intervention: Unifocal right-sided ablation under computed tomographic guidance
Number of subjects: 0
Study 33999786 — intervention group
Group type: EXPERIMENTAL
Intervention: D/C/F/TAF 800/150/200/10 mg
Number of subjects: 109
Study 34000061 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric telemedicine assessment by a board-certified geriatrician
Number of subjects: 50
Study 34000061 — intervention group
Group type: COMPARATOR
Intervention: Standard ED treatment
Number of subjects: 50
Study 34000061 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric telemedicine assessment
Number of subjects: 50